| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.05 | 0.4 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | birinapant | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | BRD-K78574327 | CTRPv2 | pan-cancer | AAC | -0.066 | 0.4 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.051 | 0.4 |
| mRNA | CAY10603 | GDSC1000 | pan-cancer | AAC | -0.026 | 0.4 |